Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia
Autore:
Kasper, S;
Indirizzi:
Univ Vienna, Dept Gen Psychiat, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 t Gen Psychiat, A-1090 Vienna, Austria
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 6, volume: 13, anno: 1998,
pagine: 253 - 262
SICI:
0268-1315(199811)13:6<253:RAOODF>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; NEGATIVE SYMPTOMS; HALOPERIDOL; TRIAL; MULTICENTER; REDUCTION; DIAGNOSIS; SEROTONIN; DISORDERS; PLACEBO;
Keywords:
clinical trial; dose; efficacy; extrapyramidal symptoms; olanzapine; risperidone; schizophrenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
51
Recensione:
Indirizzi per estratti:
Indirizzo: Kasper, S Univriaenna, Dept Gen Psychiat, Wahringer Gurtel 18-20, A-1090 Vienna, Aust Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 , Aust
Citazione:
S. Kasper, "Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia", INT CLIN PS, 13(6), 1998, pp. 253-262

Abstract

Schizophrenia is a chronic and debilitating disorder whose effective pharmacological management is often less than optimal. For several decades, pharmaceutical treatment for this disorder consisted of conventional neuroleptics such as haloperidol and chlorpromazine. However, the limitations of these drugs have driven the development of newer antipsychotics that are designed to be more efficacious and more tolerable than conventional agents. Newer agents available for consideration as first-line treatment options now include risperidone, olanzapine, sertindole and, more recently, quetiapine. Proper dosing has emerged as a vital factor in the effective use of these newer drugs. This report examines data derived from clinical trials and market research with risperidone and olanzapine to help clinicians determine theappropriate dose for efficacy and to appraise the adverse events associated with that efficacious dose. Current information suggests that, for most patients with schizophrenia, the optimal dose with respect to efficacy and tolerability of risperidone is less than or equal to 6 mg/day. The optimal dose of olanzapine is less clear and may be 15 mg/day or higher. With the advent of these newer antipsychotics, clinicians now have more treatment options for the management of patients,vith psychotic disorders. Knowledge gained through clinical experience is needed to augment clinical trial results and to help define the most effective use of each of these agents. Int ClinPsychopharmacol 13-253-262 (C) 1998 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 06:27:55